Drug intelligence / Profile preview

rabies vaccine (N. R. Biotech)

Development stage
Unknown
Lead developer
N. R. Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Intradermal
01

Overview

Surerab (also known as SURE RAB) is an inactivated, purified, and lyophilized cell culture-derived rabies vaccine developed and marketed by N. R. Biotech. The vaccine is prepared from the Pitman Moore strain of the rabies virus and is indicated for both pre-exposure and post-exposure prophylaxis against rabies in individuals of all age groups. Clinical evaluation in a Phase III randomized, open-label trial demonstrated that Surerab is comparable to the reference vaccine VERORAB in terms of safety and immunogenicity, with all subjects achieving protective antibody titers (≥0.5 IU/mL). While N. R. Biotech is identified as a developer and supplier in the context, it is also noted as a distributor of generic pharmaceutical products in India.

Brand names
SurerabSure Rab
Other names
anti-rabies vaccineinactivated rabies vaccinepurified cell culture rabies vaccinePVRV
02

Targets

RABV-G (Rabies virus glycoprotein)Rabies virus nucleoprotein (N protein)

Beyond the preview

Go deeper on rabies vaccine (N. R. Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabies vaccine (N. R. Biotech).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call